135 related articles for article (PubMed ID: 24833297)
21. Matrix biology of idiopathic pulmonary fibrosis: a workshop report of the national heart, lung, and blood institute.
Thannickal VJ; Henke CA; Horowitz JC; Noble PW; Roman J; Sime PJ; Zhou Y; Wells RG; White ES; Tschumperlin DJ
Am J Pathol; 2014 Jun; 184(6):1643-51. PubMed ID: 24726499
[TBL] [Abstract][Full Text] [Related]
22. Sirtuin 7 is decreased in pulmonary fibrosis and regulates the fibrotic phenotype of lung fibroblasts.
Wyman AE; Noor Z; Fishelevich R; Lockatell V; Shah NG; Todd NW; Atamas SP
Am J Physiol Lung Cell Mol Physiol; 2017 Jun; 312(6):L945-L958. PubMed ID: 28385812
[TBL] [Abstract][Full Text] [Related]
23. Redox signaling in aging kidney and opportunity for therapeutic intervention through natural products.
Chen YY; Yu XY; Chen L; Vaziri ND; Ma SC; Zhao YY
Free Radic Biol Med; 2019 Sep; 141():141-149. PubMed ID: 31199964
[TBL] [Abstract][Full Text] [Related]
24. TNF-α-induced NF-κB activation promotes myofibroblast differentiation of LR-MSCs and exacerbates bleomycin-induced pulmonary fibrosis.
Hou J; Ma T; Cao H; Chen Y; Wang C; Chen X; Xiang Z; Han X
J Cell Physiol; 2018 Mar; 233(3):2409-2419. PubMed ID: 28731277
[TBL] [Abstract][Full Text] [Related]
25. Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis.
Cameli P; Carleo A; Bergantini L; Landi C; Prasse A; Bargagli E
Inflammation; 2020 Feb; 43(1):1-7. PubMed ID: 31297749
[TBL] [Abstract][Full Text] [Related]
26. An inhibitor of NADPH oxidase-4 attenuates established pulmonary fibrosis in a rodent disease model.
Jarman ER; Khambata VS; Cope C; Jones P; Roger J; Ye LY; Duggan N; Head D; Pearce A; Press NJ; Bellenie B; Sohal B; Jarai G
Am J Respir Cell Mol Biol; 2014 Jan; 50(1):158-69. PubMed ID: 23977848
[TBL] [Abstract][Full Text] [Related]
27. miR-9-5p suppresses pro-fibrogenic transformation of fibroblasts and prevents organ fibrosis by targeting NOX4 and TGFBR2.
Fierro-Fernández M; Busnadiego Ó; Sandoval P; Espinosa-Díez C; Blanco-Ruiz E; Rodríguez M; Pian H; Ramos R; López-Cabrera M; García-Bermejo ML; Lamas S
EMBO Rep; 2015 Oct; 16(10):1358-77. PubMed ID: 26315535
[TBL] [Abstract][Full Text] [Related]
28. NADPH oxidase-mediated induction of reactive oxygen species and extracellular matrix deposition by insulin-like growth factor binding protein-5.
Yasuoka H; Garrett SM; Nguyen XX; Artlett CM; Feghali-Bostwick CA
Am J Physiol Lung Cell Mol Physiol; 2019 Apr; 316(4):L644-L655. PubMed ID: 30810066
[TBL] [Abstract][Full Text] [Related]
29. Mechanistic links between aging and lung fibrosis.
Thannickal VJ
Biogerontology; 2013 Dec; 14(6):609-15. PubMed ID: 23929205
[TBL] [Abstract][Full Text] [Related]
30. Idiopathic Pulmonary Fibrosis: New and Emerging Treatment Options.
Hewitt RJ; Maher TM
Drugs Aging; 2019 Jun; 36(6):485-492. PubMed ID: 30864023
[TBL] [Abstract][Full Text] [Related]
31. NADPH oxidases: Pathophysiology and therapeutic potential in age-associated pulmonary fibrosis.
Kato K; Hecker L
Redox Biol; 2020 Jun; 33():101541. PubMed ID: 32360174
[TBL] [Abstract][Full Text] [Related]
32. IPF lung fibroblasts have a senescent phenotype.
Álvarez D; Cárdenes N; Sellarés J; Bueno M; Corey C; Hanumanthu VS; Peng Y; D'Cunha H; Sembrat J; Nouraie M; Shanker S; Caufield C; Shiva S; Armanios M; Mora AL; Rojas M
Am J Physiol Lung Cell Mol Physiol; 2017 Dec; 313(6):L1164-L1173. PubMed ID: 28860144
[TBL] [Abstract][Full Text] [Related]
33. NADPH oxidase-4 mediates myofibroblast activation and fibrogenic responses to lung injury.
Hecker L; Vittal R; Jones T; Jagirdar R; Luckhardt TR; Horowitz JC; Pennathur S; Martinez FJ; Thannickal VJ
Nat Med; 2009 Sep; 15(9):1077-81. PubMed ID: 19701206
[TBL] [Abstract][Full Text] [Related]
34. The pathogenesis of bleomycin-induced lung injury in animals and its applicability to human idiopathic pulmonary fibrosis.
Williamson JD; Sadofsky LR; Hart SP
Exp Lung Res; 2015 Mar; 41(2):57-73. PubMed ID: 25514507
[TBL] [Abstract][Full Text] [Related]
35. Hallmarks of the ageing lung.
Meiners S; Eickelberg O; Königshoff M
Eur Respir J; 2015 Mar; 45(3):807-27. PubMed ID: 25657021
[TBL] [Abstract][Full Text] [Related]
36. The Aging Lung and Idiopathic Pulmonary Fibrosis.
Gulati S; Thannickal VJ
Am J Med Sci; 2019 May; 357(5):384-389. PubMed ID: 31010465
[TBL] [Abstract][Full Text] [Related]
37. Effects of hypoxia and hyperoxia on the differential expression of VEGF-A isoforms and receptors in Idiopathic Pulmonary Fibrosis (IPF).
Barratt SL; Blythe T; Ourradi K; Jarrett C; Welsh GI; Bates DO; Millar AB
Respir Res; 2018 Jan; 19(1):9. PubMed ID: 29334947
[TBL] [Abstract][Full Text] [Related]
38. Idiopathic Pulmonary Fibrosis: A Systemic Disease?
Man L; Hong P
Chin Med J (Engl); 2017 Sep; 130(17):2140-2141. PubMed ID: 28836568
[No Abstract] [Full Text] [Related]
39. Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.
Huang Q; Chen Y; Shen S; Wang Y; Liu L; Wu S; Xu W; Zhao W; Lin M; Wu J
Aging (Albany NY); 2020 Apr; 12(7):5812-5831. PubMed ID: 32244228
[TBL] [Abstract][Full Text] [Related]
40. Pathogenesis of idiopathic pulmonary fibrosis.
Wolters PJ; Collard HR; Jones KD
Annu Rev Pathol; 2014; 9():157-79. PubMed ID: 24050627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
